172 related articles for article (PubMed ID: 23086302)
1. HER2 Ile655Val and PTEN IVS4 polymorphisms in patients with breast cancer.
Ozturk O; Canbay E; Kahraman OT; Fatih Seyhan M; Aydogan F; Celik V; Uras C
Mol Biol Rep; 2013 Feb; 40(2):1813-8. PubMed ID: 23086302
[TBL] [Abstract][Full Text] [Related]
2. Association between PTEN IVS4 polymorphism and development of colorectal cancer in a Turkish population.
Canbay E; Kahraman OT; Bugra D; Caykara B; Seyhan MF; Bulut T; Yamaner S; Ozturk O
Expert Opin Ther Targets; 2013 Jan; 17(1):1-6. PubMed ID: 23062208
[TBL] [Abstract][Full Text] [Related]
3. Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer.
Han X; Diao L; Xu Y; Xue W; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Ann Oncol; 2014 Jun; 25(6):1158-64. PubMed ID: 24608202
[TBL] [Abstract][Full Text] [Related]
4. Increased gastric cancer risk with PTEN IVS4 polymorphism in a Turkish population.
Canbay E; Kahraman OT; Bugra D; Caykara B; Seyhan MF; Bulut T; Yamaner S; Ozturk O
Genet Test Mol Biomarkers; 2013 Mar; 17(3):249-53. PubMed ID: 23402578
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases.
Naidu R; Yip CH; Taib NA
Neoplasma; 2008; 55(2):87-95. PubMed ID: 18237245
[TBL] [Abstract][Full Text] [Related]
6. PTEN polymorphisms and the risk of esophageal carcinoma and gastric cardiac carcinoma in a high incidence region of China.
Ge H; Cao YY; Chen LQ; Wang YM; Chen ZF; Wen DG; Zhang XF; Guo W; Wang N; Li Y; Zhang JH
Dis Esophagus; 2008; 21(5):409-15. PubMed ID: 19125794
[TBL] [Abstract][Full Text] [Related]
7. Impact of PTEN IVS4 Polymorphism (rs3830675) on Cancer Susceptibility: An Updated Meta-analysis.
Wang Y; Yang H; Luo JI; Ge J
Cancer Genomics Proteomics; 2015; 12(5):263-9. PubMed ID: 26417029
[TBL] [Abstract][Full Text] [Related]
8. P53 codon 72 and HER2 codon 655 polymorphisms in Turkish breast cancer patients.
Kara N; Karakus N; Ulusoy AN; Ozaslan C; Gungor B; Bagci H
DNA Cell Biol; 2010 Jul; 29(7):387-92. PubMed ID: 20380571
[TBL] [Abstract][Full Text] [Related]
9. HER2 Ile655Val polymorphism contributes to breast cancer risk: evidence from 27 case-control studies.
Lu S; Wang Z; Liu H; Hao X
Breast Cancer Res Treat; 2010 Dec; 124(3):771-8. PubMed ID: 20401632
[TBL] [Abstract][Full Text] [Related]
10. Association between PTEN Gene IVS4 polymorphism and risk of cancer: a meta-analysis.
Sun L; Liu J; Yuan Q; Xing C; Yuan Y
PLoS One; 2014; 9(6):e98851. PubMed ID: 24901890
[TBL] [Abstract][Full Text] [Related]
11. Association between the Arg72Pro Genotypes in the TP53 Gene and Ile655Val in the HER2 Gene and the Risk of Developing Breast Cancer in the Population of Amapá, Northern Brazil.
Cardoso YMN; Resque RL; Yoshio D; B Miranda AR; Secco M; Do N Rodrigues AS
Asian Pac J Cancer Prev; 2023 Jan; 24(1):157-162. PubMed ID: 36708564
[TBL] [Abstract][Full Text] [Related]
12. HER2 Codon 655 (Ile/Val) Polymorphism and Breast Cancer in Austrian Women.
Watrowski R; Castillo-Tong DC; Wolf A; Schuster E; Fischer MB; Speiser P; Zeillinger R
Anticancer Res; 2015 Nov; 35(11):5901-4. PubMed ID: 26504013
[TBL] [Abstract][Full Text] [Related]
13. Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk.
Xie D; Shu XO; Deng Z; Wen WQ; Creek KE; Dai Q; Gao YT; Jin F; Zheng W
J Natl Cancer Inst; 2000 Mar; 92(5):412-7. PubMed ID: 10699071
[TBL] [Abstract][Full Text] [Related]
14. The erbB2/HER2/neu receptor polymorphism Ile655Val and breast cancer risk.
Cox DG; Hankinson SE; Hunter DJ
Pharmacogenet Genomics; 2005 Jul; 15(7):447-50. PubMed ID: 15970791
[TBL] [Abstract][Full Text] [Related]
15. A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer.
Nelson SE; Gould MN; Hampton JM; Trentham-Dietz A
Breast Cancer Res; 2005; 7(3):R357-64. PubMed ID: 15987431
[TBL] [Abstract][Full Text] [Related]
16. A case-control study of the HER2 Ile655Val polymorphism and risk of breast cancer in Taiwan.
Lee SC; Hou MF; Hsieh PC; Wu SH; Hou LA; Ma H; Tsai SM; Tsai LY
Clin Biochem; 2008 Feb; 41(3):121-5. PubMed ID: 18062925
[TBL] [Abstract][Full Text] [Related]
17. HER2 polymorphism and breast cancer risk in Portugal.
Pinto D; Vasconcelos A; Costa S; Pereira D; Rodrigues H; Lopes C; Medeiros R
Eur J Cancer Prev; 2004 Jun; 13(3):177-81. PubMed ID: 15167216
[TBL] [Abstract][Full Text] [Related]
18. The genetic variants in the PTEN/PI3K/AKT pathway predict susceptibility and CE(A)F chemotherapy response to breast cancer and clinical outcomes.
Li X; Zhang R; Liu Z; Li S; Xu H
Oncotarget; 2017 Mar; 8(12):20252-20265. PubMed ID: 28423632
[TBL] [Abstract][Full Text] [Related]
19. ABCB1 C3435T gene polymorphism as a potential biomarker of clinical outcomes in HER2-positive breast cancer patients.
Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Segura-Pérez AM; Chamorro-Santos C; Vergara-Alcaide E; Castillo-Portellano L; Calleja-Hernández MÁ
Pharmacol Res; 2016 Jun; 108():111-118. PubMed ID: 27137881
[TBL] [Abstract][Full Text] [Related]
20. Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity.
Beauclair S; Formento P; Fischel JL; Lescaut W; Largillier R; Chamorey E; Hofman P; Ferrero JM; Pagès G; Milano G
Ann Oncol; 2007 Aug; 18(8):1335-41. PubMed ID: 17693647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
